Cystic Fibrosis Foundation - Click here for homepage
Stay Informed  |  Volunteer  |  Clinical Trials

In This Section

Quick Links

Find a Chapter

Get Assistance

Get Assistance - Cox Boys
We are here to help people with CF get the insurance coverage they need. Hear how the Foundation helped the Cox family.

Join us on Facebook!  Facebook 
Follow us on Twitter!   Twitter
Follow us on Instagram!  Instagram 
Add us to your circle in Google+!


Subscribe to our channel on YouTube!  YouTube  



Bookmark and Share   Print  

Vertex Releases Promising Phase 2 Results of Ivacaftor in Residual Function Mutations of CF

June 4, 2014

Vertex Pharmaceuticals Inc. today announced preliminary results from a Phase 2 proof-of-concept study of ivacaftor (Kalydeco™) in people with cystic fibrosis who have what are known as “residual function” mutations of CF. The results showed improvements in lung function after two weeks of treatment. Vertex plans to initiate a larger Phase 3 trial to study the drug over a longer period of time in people with residual function mutations, pending discussions with regulatory authorities.

“These promising results are an important part of ongoing efforts to bring effective treatments to all people with cystic fibrosis,” said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. 

Read the Vertex press release.

The Cystic Fibrosis Foundation is an accredited charity of the Better Business Bureau.